Loading stock data…
HAE
$59.26-0.83 (-1.38%)
Market ClosedLast close May 1
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Haemonetics Corporation in the Healthcare sector is trading at $59.26. The stock is currently 32% below its 52-week high of $87.32, remaining 6.7% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why HAE maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$59.26
Potential Upside
28.2%
Whystock Fair Value$75.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$84.60+42.8%
Range$64.00 – $108.00
Fundamentals
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting sof...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.86B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.84
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.92%
Volume
Today's trading volume
618,682
Recent News
Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative
Haemonetics Corporation recently presented data at the Heart Rhythm Society 2026 Annual Meeting in Chicago showing its VASCADE MVP XL vascular closure system delivers effective hemostasis and maintains a consistent safety profile in large-bore venous access procedures, following expanded FDA labeling in March 2026 for use with procedural sheaths up to 17F outer diameter. This makes VASCADE MVP XL the only clinically proven extravascular venous closure system for sheaths up to 17F,...
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q1 2026 investor letter. A copy of the letter can be downloaded here. In Q1 2026, the Riverwater Sustainable Value Strategy underperformed the Russell 2500 Value Index. The underperformance was driven entirely by stock selection, while sector allocation contributed positively. The quarter demonstrated a […]
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review
We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Haemonetics Corporation is among the best healthcare stocks to invest in. TheFly reported on April 13 that Mizuho analyst Anthony Petrone reduced the price target for HAE to $70 from $80 while maintaining an Outperform rating. The […]
1 Value Stock on Our Buy List and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness
If you are wondering whether Haemonetics at around US$56.36 is starting to look attractively priced, the recent share performance gives you a lot to think about. The stock has seen a 0.5% decline over the last week, an 11.0% decline over 30 days and is down 29.5% year to date, with a 10.6% decline over the past year in addition to longer term 3 year and 5 year declines of 32.1% and 50.3% respectively. Recent coverage has focused on Haemonetics as a medical equipment company in the healthcare...